Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

Shohei Yamamoto; Ami Fukunaga; Akihito Tanaka; Junko S Takeuchi; Yosuke Inoue; Moto Kimura; Kenji Maeda; Gohzoh Ueda; Tetsuya Mizoue; Mugen Ujiie; Wataru Sugiura; Norio Ohmagari

doi:10.1016/j.vaccine.2022.02.052

Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

Vaccine. 2022 Mar 18;40(13):1924-1927. doi: 10.1016/j.vaccine.2022.02.052. Epub 2022 Feb 14.

Authors

Affiliations

¹ Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
² Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
³ Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
⁴ Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
⁵ Division of Core Diagnostics, Abbott Japan LLC, Tokyo, Japan.
⁶ Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: mizoue@hosp.ncgm.go.jp.
⁷ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
⁸ Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.

Abstract

High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.

Keywords: BNT162b2 vaccine; Fever; Reactogenicity; SARS-CoV-2; Spike IgG titer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
SARS-CoV-2

Substances

Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine